Balancing the Burden of Moderate to Severe Atopic Dermatitis in Pediatric Patients: Navigating the Use of Targeted Biologic Therapies and Caregiver Challenges

This activity was originally broadcast in conjunction with Asembia Specialty Pharmacy Day of Education 2024.

Program Description

Pediatric patients living with moderate to severe atopic dermatitis (AD) often endure heightened itch, skin pain, sleep disturbances, diminished health-related quality of life for them and their caregivers, and increased school absenteeism compared with those with mild AD. The treatment landscape for AD has expanded considerably, now encompassing biologics. With a number of advancements, pharmacists require additional education about the treatment and management of moderate to severe AD in pediatric patients with respect to the use of biologics. Real-world studies indicate that biologics effectively target and reduce type 2 inflammation, a critical factor in pediatric AD. Clinical evidence continues to expand regarding the role of biologic therapy for the treatment of moderate to severe pediatric AD; therefore, it is imperative that specialty pharmacists are educated on the most current efficacy and safety data of therapies used in the treatment of pediatric AD. This activity will address advances in the management of moderate to severe pediatric AD and how to improve patient access to biologic therapies that may augment clinical outcomes. This program will feature social insights collected from artificial intelligence algorithms from patients, caregivers, and health care professionals, specifically to address treatment options and strategies for overcoming access barriers in pediatric AD.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: November 12, 2024
Expiration date: November 12, 2025

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the psychosocial impact and treatment burden of pediatric atopic dermatitis (AD) on the quality of life for patients and their caregivers
• Examine the safety and efficacy profiles of approved and emerging biologics for use in pediatric patients with moderate to severe AD, including considerations for patient age, disease severity, and comorbidities
• Analyze comprehensive care plans for pediatric patients with AD that incorporate biologic therapies and counseling for caregivers

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-314-H01-P. The activity is available for CE credit through November 12, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Monica Dougherty, PharmD, BCACP, has the following relevant financial relationship with a commercial interest to disclose:

Consultant: Pfizer Inc

Emily Gurnee, MD, has the following relevant financial relationships with commercial interests to disclose:

Consultant: UpToDate, Inc

Other Support: Pfizer Inc (PI on multisite industry sponsored trial)

Aderonke Adeboye, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms